Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Argenica Therapeutics Ltd ( (AU:AGN) ) is now available.
Argenica Therapeutics Limited has been awarded up to $1.5 million in non-dilutive funding from the Australian Government’s Medical Research Future Fund Targeted Translation Research Accelerator program. This funding will support the company’s upcoming global Phase 2b/3 clinical trial of ARG-007, aimed at reducing disability following acute ischaemic stroke. The first tranche of $1 million has been secured, with an additional $500,000 contingent on successful completion and commercial potential. This financial boost positions Argenica to advance its clinical trials and retain full ownership of its intellectual property, potentially enhancing its market position in the biotechnology sector.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$1.14 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics aimed at reducing brain tissue death following strokes and other brain injuries. Their lead product, ARG-007, is a neuroprotective peptide that has shown promise in improving outcomes in pre-clinical models of stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy. The company is actively conducting clinical trials to further assess the efficacy and safety of ARG-007.
Average Trading Volume: 107,226
Technical Sentiment Signal: Buy
For detailed information about AGN stock, go to TipRanks’ Stock Analysis page.